These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
718 related articles for article (PubMed ID: 16427163)
21. Predicting and comparing long-term measles antibody profiles of different immunization policies. Lee MS; Nokes DJ Bull World Health Organ; 2001; 79(7):615-24. PubMed ID: 11477964 [TBL] [Abstract][Full Text] [Related]
22. [Susceptibility to measles, rubella and parotitis in young adults]. Bayas JM; Vilella A; Vidal J; Nebot X; Carbó JM; Navarro G; Prat A; Asenjo MA; Salleras L Med Clin (Barc); 1996 Apr; 106(15):561-4. PubMed ID: 8656753 [TBL] [Abstract][Full Text] [Related]
23. Rubella control in Papua New Guinea: age-specific immunity informs strategies for introduction of rubella vaccine. Riddell M; Senn N; Clements CJ; Hobday L; Cowie B; Kurubi J; Kevin A; Siba P; Reeder JC; Morgan C Vaccine; 2012 Dec; 30(52):7506-12. PubMed ID: 23103194 [TBL] [Abstract][Full Text] [Related]
24. The strategy for prevention of measles and rubella prevalence with measles-rubella (MR) vaccine in Japan. Ihara T Vaccine; 2009 May; 27(24):3234-6. PubMed ID: 19366578 [TBL] [Abstract][Full Text] [Related]
25. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. LeBaron CW; Beeler J; Sullivan BJ; Forghani B; Bi D; Beck C; Audet S; Gargiullo P Arch Pediatr Adolesc Med; 2007 Mar; 161(3):294-301. PubMed ID: 17339511 [TBL] [Abstract][Full Text] [Related]
26. Response to measles, mumps, and rubella revaccination among HIV-positive and HIV-negative children and adolescents with hemophilia. Hemophilia Growth and Development Study. Hilgartner MW; Maeder MA; Mahoney EM; Donfield SM; Evatt BL; Hoots WK Am J Hematol; 2001 Feb; 66(2):92-8. PubMed ID: 11421305 [TBL] [Abstract][Full Text] [Related]
27. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bennett JV; Fernandez de Castro J; Valdespino-Gomez JL; Garcia-Garcia Mde L; Islas-Romero R; Echaniz-Aviles G; Jimenez-Corona A; Sepulveda-Amor J Bull World Health Organ; 2002; 80(10):806-12. PubMed ID: 12471401 [TBL] [Abstract][Full Text] [Related]
28. Humoral immunogenicity to measles, rubella, and varicella-zoster vaccines in biliary atresia children. Wu JF; Ni YH; Chen HL; Hsu HY; Lai HS; Chang MH Vaccine; 2009 May; 27(21):2812-5. PubMed ID: 19366583 [TBL] [Abstract][Full Text] [Related]
29. Immune response to measles vaccine after mass vaccination in Urmia, Islamic Republic of Iran. Yekta Z; Pourali R; Taravati MR; Shahabi S; Salary S; Khalily F; Farzin A East Mediterr Health J; 2009; 15(3):516-25. PubMed ID: 19731767 [TBL] [Abstract][Full Text] [Related]
30. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Paunio M; Hedman K; Davidkin I; Valle M; Heinonen OP; Leinikki P; Salmi A; Peltola H Epidemiol Infect; 2000 Apr; 124(2):263-71. PubMed ID: 10813152 [TBL] [Abstract][Full Text] [Related]
31. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy. Sultana R; Rahman MM; Hassan Z; Hassan MS Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626 [TBL] [Abstract][Full Text] [Related]
32. Seroconversion after measles vaccination at nine and fifteen months of age. Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768 [TBL] [Abstract][Full Text] [Related]
33. [Antibody development and frequency of events temporarily associated with measles and rubella vaccines among university health personnel in Jalisco]. Villaseñor-Sierra A; Santos-Preciado JI; Alvarez-y-Muñoz MT; Rivas-García ME; Martínez-Sandoval F; Falcón-Franco MA Gac Med Mex; 2005; 141(6):455-9. PubMed ID: 16381498 [TBL] [Abstract][Full Text] [Related]
34. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. Should we be concerned? Watada B; Kennedy K; Chan D; Church B; Patriquin M; Shariff F; Evans MF Can Fam Physician; 1998 Jan; 44():53-5. PubMed ID: 9481462 [No Abstract] [Full Text] [Related]
35. Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults. Cohn ML; Robinson ED; Faerber M; Thomas D; Geyer S; Peters S; Martin M; Martin A; Sobel D; Jones R Pediatr Infect Dis J; 1994 Jan; 13(1):34-8. PubMed ID: 8170730 [TBL] [Abstract][Full Text] [Related]
36. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ; Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343 [TBL] [Abstract][Full Text] [Related]
37. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100 [TBL] [Abstract][Full Text] [Related]
38. Measles revaccination response in a school-age population. Wittler RR; Veit BC; McIntyre S; Schydlower M Pediatrics; 1991 Nov; 88(5):1024-30. PubMed ID: 1945606 [TBL] [Abstract][Full Text] [Related]
39. Study of antibody titres after measles vaccination: fever within 7 days of vaccination and efficacy of booster doses. Egami T; Egami K; Tanoue A Arch Dis Child; 2008 Apr; 93(4):319-20. PubMed ID: 17488762 [TBL] [Abstract][Full Text] [Related]